Daily Stock List
China Pharma Holdings, Inc. (CPHI)
Greenbackers, PennyOmega, China Vesting, and Wall Street Resources reported previously on China Pharma Holdings, Inc. (CPHI), and we highlight the Company, here at the QualityStocks Daily Newsletter.
China Pharma Holdings, Inc. principally engages in the development, manufacture, packaging, marketing and distribution of generic and branded pharmaceutical products for a wide spectrum of high incidence and high mortality conditions in The People's Republic of China (PRC). The Company's primary focus for their therapeutics includes CNS, cardiovascular, cerebrovascular, wound recovery, digestive disease, and infectious diseases. China Pharma conducts all of their operations in the PRC. The Company's wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province.
China Pharma has an 8,000-square-meter manufacturing facility in the PRC. The Company has eight GMP (Good Manufacturing Practice) certified production lines. China Pharma has the capacity to produce drugs in a variety of delivery mechanisms including freeze dried (lyophilized injectables), capsules, tablets, granules, injectables, and oral fluids (suspension). More than 90 percent of their pharmaceutical products sell on a prescription basis and have approval for at least one or more therapeutic indications by the Chinese State Food and Drug Administration (SFDA) based upon demonstrated safety and efficacy.
At September 30, 2011, China Pharma manufactured 20 pharmaceutical products for a wide variety of diseases and medical indications, each of which may be classified into one of three general categories. One is a basic generic drug, which is a common drug in the PRC marketplace for which there is a very large market. The second is a "super" or "first to market" generic drug, which is a generic Western drug that is new to the PRC marketplace.
The third is a modern Traditional Chinese Medicine, which usually is a non-synthetic, plant-based medicinal compound of the type that has been widely used in the PRC for thousands of years. To these the Company applies modern production techniques to produce a pharmaceutical product in different formulations, such as tablets, capsules or powders.
China Pharma markets and sells their products through 16 sales offices covering all major cities and provinces in the PRC. To comply with applicable Chinese law relating to sales of prescription drugs to certain hospitals and clinics, the Company also uses a distribution system consisting of approximately 1,250 independent regional distributors.
Yesterday, China Pharma Holdings announced financial results for the quarter ended March 31, 2012. Revenue was $16.1 million, compared to $18.1 million in the prior year period. Gross profit was $5.3 million, compared to $6.9 million in the prior year period. Operating income was $3.4 million, compared to $5.3 million in the prior year period. Net income was $2.8 million, or $0.06 per basic and diluted share, compared to $5.3 million in the prior year period, or $0.12 per basic and diluted share.
China Pharma Holdings, Inc. (CPHI), closed on Wednesday at $0.39, down 9.30%, on 34,944 volume with 71 trades. The average volume for the last 60 days is 73,114. The 52-week low/high is $0.46/$2.75.
Li-ion Motors Corp. (LIMO)
Fast Moving Stocks reported this month on Li-ion Motors Corp. (LIMO), Smackdown Penny Stocks, Michael Stone, PickPennyStocks, Growing Stocks Reports did last month, and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTC Bulletin Board, Li-ion Motors Corp. is a pioneer in the advanced development of Lithium Ion battery technology. The Company is a leading developer and manufacturer of electric powered automobiles including the X-Prize winning WAVE II and the Inizio all electric supercar. The WAVE II and Inizio are in the process of DOT Certification; upon completion, they will undergo release to the public. Formed in 2000, Li-ion Motors has their headquarters in Mooresville, North Carolina and corporate offices in Las Vegas, Nevada.
Li-ion's Inizio, designed and built in the Company's Mooresville facility, is a 100 percent electric supercar. It is capable of 170 mph with acceleration from 0-60 mph in 3.4 seconds. The car has zero emissions, a 114-inch wheelbase and a 78-inch wide footprint. The Inizio is stable at high speeds. The Company also created the WAVE II. This is a two-seat all-electric, zero emission commuter car with a 202.5 MPGe, as rated by the Argonne National Lab (US Department of Energy). The WAVE II was the winner of the 2010 Progressive Automotive X-Prize in the side-by-side competition.
Li-ion Motors' customer base extends to many countries. These countries include Israel, Canada, the Netherlands, and the United Arab Emirates (UAE). In December 2007, Li-ion was the first company to deliver a high speed, extended range, all Lithium Electric car to a retail consumer anywhere in the world through the "Once in a Lifetime" offer with Sam's Club and NASA.
Concerning R & D developments, Li-ion is developing an in-house motor controller to work with their Patented Battery Management System (BMS) that will continue to increase efficiency. Li-ion is further enhancing the performance of the INIZO with dual motors, a 5 speed sequential transmission and high performance capacitor.
In April, Li-ion Motors reported up to a 40 percent reduction in charging time with engineering advancement on the Company's new internally designed and engineered charging system. Their engineers are hopeful that with further testing, research, and development charging costs can be decreased by up to 25 percent. Li-ion has converted PT Cruisers, Mini Coopers, Toyota Yaris', Pontiac Vibes, trucks, and motorcycles.
Li-ion Motors Corp. (LIMO), closed on Wednesday at $0.07, up 12.72%, on 5,000 volume. The average volume for the last 60 days is 182,394. The 52-week low/high is $0.05/$4.10.
American CareSource Holdings, Inc. (ANCI)
PennyTrader Publisher reported earlier on American CareSource Holdings, Inc. (ANCI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
American CareSource Holdings, Inc. is the first national, publicly traded ancillary care network services company. They offer a comprehensive national network of over 4,800 ancillary service providers at more than 38,000 sites through their subsidiary, Ancillary Care Services. In operation since 1997, American CareSource has their corporate headquarters in Dallas, Texas.
Ancillary Care Services offers the regional payer community access to a wide network of ancillary providers, along with a value-added suite of services that results in quantifiable medical and operational cost savings to payors. Ancillary Care Services provides ancillary health care services through their network that offers cost-effective alternatives to physician and hospital-based services.
These providers offer services in 31 categories. These include laboratories, dialysis centers, freestanding diagnostic imaging centers, and non-hospital surgery centers. They also include durable medical equipment such as orthotics and prosthetics and others.
The Company's ancillary network and management provide a complete outsourced solution for a broad array of health care payors and plan sponsors. These include self-insured employers, indemnity insurers, PPOs, HMOs, third-party administrators and both federal and local governments.
This month, American CareSource Holdings introduced their new DiaSource™ solution for containment of dialysis costs. The solution is from their subsidiary Ancillary Care Services (ACS), the leading national network of ancillary healthcare providers. Through the DiaSource suite of services, employers can access the DiaSource high-performance network (HPN) — a network of dialysis providers that have agreed to low, competitive rates. The patient's dialysis costs are covered at 100 percent. The employer has low predictable costs throughout the course of treatment.
Last week, American CareSource Holdings reported revenue of $9.4 million for the first quarter of 2012, compared to $13.1 million for the same period in 2011. Net loss for the quarter was $558,000 compared to a net loss of $222,000 for the prior-year period.
During the first quarter, revenue from the Company's Third-Party Administrator (TPA) clients grew $924,000 or 24 percent, and Ancillary Care Services added another new TPA client. They also significantly increased their pipeline of prospects within the market.
American CareSource Holdings, Inc. (ANCI), closed on Wednesday at $0.4701, down 0.91%, on 19,905 volume with 19 trades. The average volume for the last 60 days is 20,154. The 52-week low/high is $0.30/$1.90.
Cryoport, Inc. (CYRX)
FeedBlitz, PennyOmega.com, HotOTC.com, CoolPennyStocks, Stock Rich, and Stockpalooza reported previously on Cryoport, Inc. (CYRX), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Founded in 1999, Cryoport, Inc. provides leading edge cold chain logistics services through the combination of purpose built proprietary technologies and total turnkey management of the entire process. The Company's total turnkey service management approach offers reliability, cost effectiveness, and convenience. The use of recyclable and reusable components provides a "green" and environmentally friendly solution. Cryoport's shares trade on the OTC Bulletin Board; the Company is based in Lake Forest, California.
Cryoport delivers an innovative and complete outsourced frozen shipping solution for biological materials. Cryoport replaces outdated dry ice and virtually eliminates the risk of cell degradation in transportation, while simplifying logistics. The Company combines the innovative technology of liquid nitrogen dry vapor shippers with the most advanced Logistics Management Platform in the industry. Cryoport also offers their logistics expertise. The Company provides a complete outsourced solution that advances deep-frozen shipping.
The Cryoport Express® liquid nitrogen dry vapor shipper is validated to maintain a constant -150°C temperature for a 10 plus day dynamic shipment duration. Their Cryoportal™ Logistics Management Platform manages the entire shipment process. This includes initial order, document preparation, customs clearance, courier management, shipment tracking, issue resolution, and delivery.
Last week, Cryoport announced that they signed an agreement with Pan Asia Logistics to open their Asian Operations Center in Singapore. The agreement calls for Pan Asia to support the Cryoport Solution by providing warehousing, shipping, receiving, order entry and fulfillment, and refurbishing and recycling of Cryoport's liquid nitrogen dry vapor shipping containers.
"Shipments of life science and biological material are growing at a strong double digit growth rate in Asia, and our partnership with Pan Asia Logistics will significantly enhance our ability to expand our services within our current customer base and drive new business," said Cryoport's Chairman Mr. Stephen Wasserman.
In addition, last week, Cryoport announced that Mr. Wasserman will present at the B. Riley 13th Annual Investor Conference at 1:30 p.m. Pacific on Monday, May 21, 2012. The conference is taking place at the Loews Santa Monica Beach Hotel. Interested parties can access a live audio webcast of the Company's presentation at www.cryoport.com.
Cryoport, Inc. (CYRX), closed on Wednesday at $0.45, up 9.76%, on 3,435 volume with 2 trades. The average volume for the last 60 days is 24,120. The 52-week low/high is $0.37/$1.73.
Immunovative, Inc. (IMUN)
We are highlighting Immunovative, Inc. (IMUN) here at the QualityStocks Daily Newsletter.
Immunovative Therapies, Ltd. (Immunovative Therapies) is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. Immunovative Therapies is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israel technological incubator program. On May 8, 2012, Novo Energies Corp. announced that the Company's name was changed to Immunovative, Inc., and that their new stock trading symbol is now (OTCBB: IMUN) effective immediately. This name and symbol change was made to reflect better the new business operations of the Company.
On December 15, 2011, Novo Energies signed an exclusive License Agreement with Immunovative Therapies. Under the terms of the License Agreement, Novo was granted an exclusive, worldwide license to commercialize any products covered under Immunovative's current issued and pending patent application portfolio, as well as the rights to any future patent applications. This includes improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products in clinical development including AlloStim™ and AlloVax™.
Immunovative Therapies was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. The Company specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for the treatment of cancer and infectious diseases.
Immunovative Therapies is developing a new class of immunotherapy drugs designed to harness the power of the immune system to treat cancer. The Company has two experimental immunotherapy products for the treatment of cancer in clinical development: AlloStim™ and AlloVax™ covered by Immunovative's 10 U.S. patents granted, 15 U.S. patents pending and 26 corresponding applications pending internationally.
AlloStim™ has completed a Phase I/II clinical study. It is currently awaiting regulatory clearance to begin a potentially pivotal Phase II/III randomized, controlled clinical study in women with refractory metastatic breast cancer. AlloVax™ has completed pre-clinical and Phase I safety studies. It is currently awaiting regulatory clearance to initiate a randomized, controlled Phase I/II clinical study in refractory head and neck cancer.
Immunovative, Inc. (IMUN), closed on Wednesday at $0.10, even with yesterday’s close, on 10,100 volume with 3 trades. The average volume for the last 60 days is 7,571. The 52-week low/high is $0.08/$0.20.
KWG Resources, Inc. (KWG.V)
Today we are reporting on KWG Resources, Inc. (KWG.V), here at the QualityStocks Daily Newsletter.
KWG Resources, Inc. is an exploration stage company whose shares trade on the TSX Venture Exchange. The Company is participating in the discovery and delineation of chromite deposits in the James Bay Lowlands of Northern Ontario. These deposits appear to promise the hosting of a globally significant source of chromite that may undergo refining into ferrochrome, a principal ingredient in the manufacture of stainless steel. Canada Chrome Corp. (CCC) was created as a wholly owned subsidiary of KWG Resources. KWG owns 100 percent of CCC. KWG has their headquarters in Montreal, Quebec.
The Company has been a pioneer in exploring the James Bay lowlands in a joint venture with Spider Resources, Inc. since 1993. This has resulted in the discovery of several diamond bearing kimberlites and the McFaulds Lake copper-zinc volcanogenic massive sulphide deposits in 2004, the discovery that precipitated a staking rush that defined the "Ring of Fire".
KWG has a 28 percent interest in the Big Daddy deposit and is currently earning an additional 2 percent interest in it under an option agreement to create a joint venture with Cliffs Natural Resources, Inc. (Project Operator) on April 1, 2012. KWG's Canada Chrome Corp. (CCC) has staked claims and conducted a $15 million surveying and soil-testing program for the engineering and construction of a railroad to the Ring of Fire from Exton, Ontario where the Trans Canada line of the Canadian National Railway can be connected.
In early March, KWG Resources announced that they completed the previously announced acquisition of 49 unpatented claims from INV Metals, Inc. in consideration of 3 million treasury units each consisting of one share and one 5-year warrant exercisable at $0.12. The claims are south of McFaulds Lake and the Ring of Fire and complete an important section of the railway corridor staked by KWG subsidiary CCC. The acquired claims also contain a potential source of aggregate material essential to the construction of any roadway or railway embankment.
Also in March, KWG Resources announced that they and their subsidiary CCC received an Order to File from the Ontario Mining and Lands Commissioner. KWG said that it appears that an application made to the Minister of Natural Resources (MNR) by 2274659 Ontario, Inc., a subsidiary of Cliffs Chromite Ontario, Inc., for the grant of an easement under s.21 of the Public Lands Act, has been referred to the Mining Commissioner by the Mining Recorder's office of the Ministry of Northern Development and Mines. The MNR, Chromite and CCC will be parties to the proceeding and will have an opportunity to submit documents and legal arguments and to participate in a hearing before the Commissioner.
KWG Resources, Inc. (KWG.V), closed on Wednesday at $0.06, down 8.33%, on 226,177 volume. The 52-week low/high is $0.06/$0.11.
Wolverine Minerals Corp. (WLV.V)
Today we are reporting on Wolverine Minerals Corp. (WLV.V), here at the QualityStocks Daily Newsletter.
Wolverine Minerals Corp. is a Canadian gold exploration company whose shares trade on the TSX Venture Exchange. The Company focuses on finding and developing economic mineral deposits in the Yukon, Canada. Wolverine Minerals' primary asset is their 25-property Wolverine Gold Portfolio with a combined land package of more than 523sq/km. The Company has their headquarters in Vancouver, British Columbia.
Wolverine Minerals is capitalizing on two key regional advantages. One is the Yukon's rapid emergence as a leading venue for mineral exploration in Canada. Underworld Resources, Kaminak Resources and Rockhaven Resources have announced major discoveries. The other advantage is Wolverine's association with Archer Cathro & Associates, the geological engineers and geoscientists who selected and prospected all the properties now under option.
The Wolverine Gold Project consists of 16 properties in the Dawson Range Gold Belt of west-central Yukon and 9 properties in the Finlayson District of eastern Yukon. Both of the areas are highly prospective for volcanogenic, orogenic and intrusion-related gold mineralization. Existing volcanogenic deposits include Wolverine and Kudz Za Kayah. The Pogo and White Gold deposit represent key orogenic deposits. Major intrusion-related deposits include Fort Knox and Mt. Nansen.
Last week, Wolverine Minerals announced that the Company finalized their 2012 exploration plans for the upcoming field season. The programs will focus on the drilling of three high priority targets as a follow up to Wolverine's extensive 2011 exploration work. The three properties to undergo drilling, starting in early June, will be the Dade and Sked/Desk (Sked) in the Dawson Range and the Vivi/Has (Vivi) in the Finlayson Lake District. The design of the drilling programs for each property is as two-phase programs.
The 1,700-hectare Dade property hosts the known gold-mineralized Grizzly Vein, which was discovered in the 1920s. The Sked and Desk mining claims collectively comprise the 850-hectare Sked property. The Vivi and Has mining claims collectively comprise the 1,400 hectare Vivi property.
Wolverine Minerals Corp. (WLV.V), closed on Wednesday at $0.12, even with yesterday’s close, on 1,500 volume. The 52-week low/high is $0.11/$0.70.
BeesFree, Inc. (BEES)
AllPennyStocks reported last week on BeesFree, Inc. (BEES), SmallCapVoice, MonsterStocksPicks, Stock Stars did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
BeesFree, Inc. is a company focusing on developing innovative solutions for the worldwide beekeeping community. The Company owns a patent pending technology that helps honeybees combat and avoid the effects of Colony Collapse Disorder (CCD). Incorporated in 2011, BeesFree has their corporate headquarters in West Palm Beach, Florida. All of the Company's Research and Development activities run in Laboratory Facilities located in Rome, Italy. BeesFree lists on the OTC Bulletin Board.
This new syndrome, the Colony Collapse Disorder (CCD), considered itself as an aggregation of deaths from multiple causes, has caused consistent colony losses in excess of 35 percent annually from 2007. In some European Union (EU) countries, it is up to 50 percent. A list of possible causes for CCD includes beekeeper management practices, new pesticides, pesticide use patterns, nutritional deficits associated with extensive monocultures, climate change, exotic parasites and pathogens, diminished immunity to pathogens and interactions among two or more of these factors.
BeesFree's patent-pending solution integrates a simple-to-use innovative dispenser and a proprietary soluble-in-water preparation consisting of several specific agents. These include antimicrobial agents and compounds to fight the IIV Virus and its interaction with Nosema. Nosema is a genus of microsporidian parasites. Specific agents also include components to contrast neonicotinoids side effects on bees, as well as nutrients and antioxidants. The Company's BeesFree Dispenser (or Beespenser) will have specific geometry and colors meant to attract bees.
Last Friday, BeesFree reported that last Thursday's news report by Brian Williams on NBC Nightly News highlighted the potential devastating effects of Colony Collapse Disorder (CCD). Mr. Williams referred to the mysterious disappearance of bees as a situation that is "as big and as urgent as any other, a story we have been talking about for a while. Something has been causing honeybees to disappear since about 2006. Beekeepers estimate their colonies are down 30 percent. Given all that bees do in the natural world, this could be catastrophic."
BeesFree, Inc. (BEES), closed on Wednesday at $2.21, up 2.31%, on 10,650 volume with 11 trades. The average volume for the last 60 days is 11,376. The 52-week low/high is $1.10/$3.25.
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.38, even with yesterday's close, on 26,660 volume with 18 trades. The stock’s average daily volume over the past 60 days is 185,187, and its 52-week low/high is $0.3412/1.20.
International Stem Cell Corp. reported financial results for the three months ended March 31, 2012, today, also detailing significant recent highlights from operations, including pre-clinical in vivo safety/efficacy in Parkinson’s (continued development of parthenogenetic stem cell lines), as well as the growth of wholly-owned subsidiary Lifeline Skin Care, and the Company’s overall solid financial position (secured some $7.03M of equity capital financing in Q1).
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corp Announces First Quarter 2012 Financial Results and Business Highlights
International Stem Cell Corporation Scientists to Present Pre-Clinical Research Results at American Society of Gene and Cell Therapy 15th Annual Meeting
International Stem Cell Corporation Announces New Stem Cell Manufacturing Technologies to Support its Therapeutic Programs
GlobalWise Investments, Inc. (GWIV)
The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $1.55, off by 3.13%, on 6,281 volume with 12 trades. The stock’s average daily volume over the past 60 days is 7,349, and its 52-week low/high is $1.02/$1.87.
GlobalWise Investments, Inc., and its wholly-owned subsidiary Intellinetics, Inc., reported financial results for the three months ended March 31, 2012 today, showing revenue up 51% and gross profit up 61% from the same interval last year, among other highlights from what was a very busy first quarter.
GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.
GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.
The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.
GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer
GlobalWise Investments Company Blog
GlobalWise Investments News:
GlobalWise Reports First Quarter 2012 Financial Results
GlobalWise Provides Shareholder Update and Reports International Expansion to Latin America
GlobalWise Announces Channel Sales Partnership With the eVero Corporation
SilverSun Technologies, Inc. (SSNT)
The QualityStocks Daily Newsletter would like to spotlight SilverSun Technologies, Inc. (SSNT). Today, SilverSun Technologies, Inc. closed trading at $0.22, even for the day, on 5,016 volume with 4 trades. The stock’s average daily volume over the past 60 days is 24,962, and its 52-week low/high is $0.005/$0.51.
SilverSun Technologies, Inc. (SSNT), via wholly-owned subsidiary SWK Technologies, is a premier total solutions provider specializing in business software for manufacturers and distributors. Established in 1988, the company focuses on meeting the needs of small-sized and mid-sized businesses ("SMB" marketplace) with accounting and business management products, including SilverSun's own proprietary software. The company also offers its own cloud-based solutions and provides network services (network configuration, data backup, 24/7 remote monitoring, etc.) to its clients.
SilverSun distinguishes itself from traditional software resellers by offering a wide range of value-added services, consisting primarily of programming, training, technical support, and other consulting and professional services. The company also provides software customization, data migration, business consulting, and implementation assistance for complex design environments. Currently, the company has over 1,000 active customers.
In addition to driving organic growth, SilverSun's aggressive growth strategy includes acquiring firms in the extensive and expanding SMB marketplace to create substantial value for its shareholders, employees, and partners. SilverSun aims to leverage SWK Technologies as a platform to roll up and aggregate the best and brightest ERP resellers, as well as other software companies with proprietary products that serve the SMB marketplace. The company's most recent acquisition was in January 2012.
In 2011, SilverSun increased sales 40% over the previous year and strengthened its balance sheet through the elimination of all outstanding debt. With organic sales accelerating, significant debt reduction, and great depth of expertise and resources, SilverSun is well positioned to become a dominant player in the growing business software marketplace. Disclaimer
SilverSun Technologies, Inc. Blog
SilverSun Technologies, Inc. News:
SilverSun Technologies Introduces Proprietary Series of Cloud-Based Business Management Solutions for $8.7 Billion Beer Brewing and Distribution Industry
SilverSun Technologies Issues CEO Letter
SilverSun Technologies Announces Subsidiary SWK Technologies Closes on Another Major Sage ERP X3 Sale
Beacon Enterprise Solutions Group, Inc. (BEAC)
The QualityStocks Daily Newsletter would like to spotlight Beacon Enterprise Solutions Group, Inc. (BEAC). Today, Beacon Enterprise Solutions Group, Inc. closed trading at $0.11, off by 8.33%, on 51,512 volume with 5 trades. The stock’s average daily volume over the past 60 days is 59,849, and its 52-week low/high is $0.0831/$0.47.
Beacon Enterprise Solutions Group, Inc. (BEAC) specializes in designing, implementing and managing high performance Information Technology Systems ("ITS") infrastructure solutions. Offering national, multi-national and global, turnkey ITS infrastructure solutions, the company is capable of delivery professional services to Fortune 1000 and large multi-site firms as they increasingly single source and outsource to reduce costs while optimizing critical planning, design, program, project and construction management and managed services.
Leveraging standardization, rapid mobilization and a just-in-time professional services approach, Beacon Enterprise Solutions serves as a single source for national, multi-national and global enterprise clients, including special practices focused on data centers, campuses, smart buildings, outside plant, wireless systems and other technology-based applications and projects. Clients are provided with consistent and predictable results anywhere in the world. The company's solutions allow clients to focus on their core businesses without the distraction of having employees spend valuable time on services that Beacon can provide on any continent, in any country using any language.
Headquartered in Louisville, Kentucky, with regional headquarters in Cincinnati, Ohio, Dublin, Ireland, and Prague, Czech Republic, in addition to personnel located throughout the United States and Europe, Beacon Enterprise Solutions services a diverse range of clients. For more than 30 years, the company has enabled businesses in a variety of vertical markets to dramatically reduce costs, enable global standardization, manage day-to-day technology systems moves, adds and changes, and take on major projects – all under a single national, multi-national or global agreement.
Beacon Enterprise Solutions has carefully assembled a seasoned management team and operating strategy to maximize organic growth and new business development across multiple vertical markets. More than 4,000 companies, from small businesses to Fortune 50 firms, have chosen the company's solutions. Disclaimer
Beacon Enterprise Solutions Group, Inc. Blog
Beacon Enterprise Solutions Group, Inc. News:
Beacon Enterprise Solutions Reports Results for Fiscal Second Quarter 2012
Beacon Enterprise Solutions Senior Management to Make Individual Voluntary Open Market Stock Purchases
Beacon Enterprise Solutions to Host Conference Call May 2, at 10:00 a.m. EDT to Discuss Fiscal Second Quarter Results
Today before the opening bell, International Stem Cell Corporation announced its financial results for the three months ended March 31, 2012.
Consolidated net revenues for the period were $1.08 million compared to $1.52 million a year earlier. The year-over-year decrease in revenues is due to fewer sales generated from the Lifeline Skin Care (LSC) direct sales channel, partially offset by higher Lifeline Cell Technology (LCT) sales generated from larger distributors. LSC and LCT accounted for 51% and 49% of total revenue in the three months ended March 31, 2012 compared to 75% and 25%, respectively, in the comparable period a year ago.
For the three months ended March 31, 2012, development expenses were $3.80 million, representing a decrease of approximately 5% compared to the corresponding period in 2011. The decrease primarily reflects lower general and administrative expenses resulting from decreased stock-based compensation expense and lower laboratory-related expenses. The decrease was partially offset by higher cost of sales ratio resulting from increased sales concentration of lower margin products, and higher marketing and selling expense related to LSC. The Company continued to invest in its sales and marketing infrastructure, including significant enhancements to the e-commerce platforms, increased advertising and strengthening the sales and customer service organization.
Cash and cash equivalents at March 31, 2012 were $6.01 million compared to $1.34 million at December 31, 2011, reflecting an increase of $4.67 million resulting from two financing transactions including the issuance of shares of Series G preferred stock for $5.00 million and issuance of shares of common stock for a total of $2.08 million in the first quarter of 2012.
The company continued to focus its research and development efforts on the creation of additional parthenogenetic stem cell lines for therapeutic use and on the advancement of the disease area research programs, particularly pre-clinical in vivo safety and efficacy studies in Parkinson’s disease and new methods for high-throughput cell culture and stem cell differentiation.
ISCO’s wholly-owned subsidiary Lifeline Skin Care drove sales by expanding acquisition of both retail and trade customers, increasing the average order value and enhancing customer loyalty and retention. New retail customers were attracted by an increased social media presence and national exposure on TV shows such as ABC’s “The Talk” and the use of risk-free introductory offers and free sample promotions. In addition, LSC continued to increase the number of strategic marketing partnerships. Although LSC revenue for the quarter was lower than the same period in 2011, the sales were generated from more diversified sources with much greater growth potential and reduced reliance on individual third parties.
Lifeline Cell Technology, ISCO’s wholly-owned subsidiary specialized in cells and media research products, grew revenue across all three sales channels including domestic, international, and OEM, showing a 39% increase over the same quarter of 2011.
The overall financial position of the company was significantly improved. ISCO increased its liquidity by securing a total $7.03 million of capital through equity financing transactions in the first quarter of 2012.
Dr. Andrey Semechkin, ISCO’s CEO and Co-Chairman, commented, “The first quarter of this year has been a challenging one for ISCO. However, with the significant improvement of our balance sheet position resulting from the closing of the financings, coupled with the addition of Dr. Berglund as a new independent director to our Board of Directors, I believe that we have strengthened our foundation on which we can increase our competitiveness.”
GlobalWise Investments, and its wholly owned subsidiary Intellinetics, a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (ECM) systems in both the public and private sectors, today announced financial results for the three months ended March 31, 2012.
The company’s total revenues for the period were $360,328, an increase of $121,202, or 51%, from the company’s first quarter 2011 results of $239,126. Moreover, gross profit increased $21,398 to $56,381 for the quarter as compared to $34,983 during the first quarter of 2011, a 61% increase.
Total operating expenses increased by $780,852 for the quarter versus the same period a year earlier. This increase is primarily due to one-time expenses and corresponding costs of public company reporting incurred when Intellinetics, Inc. merged with GlobalWise.
“We had a very busy first quarter this year and we’re extremely pleased with the direction and transformation of the company in such a short period,” stated GlobalWise’s President and CEO Mr. William J. “BJ” Santiago. “Leveraging our 18-year operating history as a software solutions provider, we’re now rapidly migrating to a cloud-based, channel distribution model with great success. For example, our substantial first quarter growth is in direct correlation to the success of on-boarding just one key channel partner in the third quarter of 2011 that serves the healthcare industry. I believe that the success we’ve had in on-boarding similar dynamic partners late last year and throughout this first quarter will replicate the same financial success over the next year. We believe the short-term, one-time expenses of the merger will be more than offset in the future by the benefits of having access to additional sources of capital as we continue to execute our growth strategy both in North America and abroad in the cloud computing sector.”
With the merger complete, GlobalWise has significantly ramped-up its sales efforts, securing five new channel partner agreements since February. The company believes the expansion of its reseller program to include Latin America in the second quarter of 2012 will continue to increase, driving growth for the next several years.
For additional information on GlobalWiseInvestments, visit the company’s website at www.GlobalWiseInvestments.com
Today, Zynex, a developer of advanced non-invasive devices for a variety of medical functions ranging from cardiac monitoring and electrotherapy, to neurological diagnosis and actual stroke rehabilitation, was pleased to announce that the Ernst & Young Entrepreneur of the Year® 2012 program (Mountain Desert region – Arizona, Colorado, and New Mexico) has named the company’s President and CEO, Thomas Sandgaard, as one of the top three finalists for this coveted award.
Only the top innovators, who have shown the ability to deliver financial performance as well as a strong dedication both to the business and the communities in which the business operates, are selected each year for recognition as outstanding entrepreneurs. Needless to say, this is a huge boon both for the company and for Mr. Sandgaard, who was selected by the independent panel of judges, and who will be on hand June 28 at the Seawell Ballroom (Denver Center for the Performing Art) gala awards ceremony.
While eager to win this crowning achievement, ZYXI’s top man knows that it is the hard work, dedication, and constant drive to excel by the entire company team, which has propelled Zynex to its position of success thus far. From rather humble beginnings in 1996, to today handling all aspects of engineering, manufacturing, marketing, and selling the wide array of (chiefly electrotherapy) pain managing and rehabilitation devices the company offers, ZYXI has had quite the meteoric rise in the medical device industry. Today the company’s fully developed line of FDA-cleared products is seen all over the world.
ZYXI consists of three divisions, each of which is dedicated to a specific area: Zynex Medical, Zynex Monitoring Solutions, and Zynex NeuroDiagnostics. Zynex NeuroDiagnostics for instance, is responsible for the superb NeuroMove device, something stroke and spinal cord injury sufferers could have only dreamt of decades ago. This strong technical platform shows abundant promise in a variety of markets and the company is rapidly moving to aggress the parallel EMG, EEG, auditory, sleep pattern, and nerve conductivity (diagnosing neurological disorders) device spaces via ongoing development of the portfolio of technology, as well as shrewd acquisitions of identified technologies with serious potential.
This will mark the 26th annual Ernst & Young Entrepreneur Of The Year award, a symbol that has come to stand for as the par excellence metric whereby to judge the potential, vision, and leadership of the best and brightest entrepreneurs. The award is a true, unique hallmark, standing as the only global award of its kind for recognizing the most dynamic and capable businesses in over 140 cities and 50 countries worldwide, driving that recognition via an ingeniously localized model (having regional, national, and also global awards in the program).
Regional winners get kicked up to the nationals and announcements will be made for the Ernst & Young National Entrepreneur of the Year Overall Award, this Nov 17, at the awards ceremony in Palm Springs, CA. The awards themselves mark a culmination of the larger Ernst & Young Strategic Growth Forum, a national assemblage of high-growth companies and market leaders.
The Entrepreneur of the Year Awards are nationally funded by SAP America and the Ewing Marion Kauffman Foundation, and are founded/produced by Ernst & Young LLP, with localized sponsorship in the Mountain Desert region coming from a variety of sources, including ADP, CliftonLarsonAllen, The Denver Business Journal, Faegre Baker Daniels, JohnstonWells Public Relations, and Scherzer International. Ernst & Young is recognized as a global leader in advisory, transaction, and tax services, as a global organization of firms, serving just about every industry you can think of.
Quite the major coup for ZYXI, which has already established a solid reputation in the medical device space and now looks to go even further after being recognized via CEO Sandgaard for exceptional performance in the space.
For more information about today’s announcement, or to learn more about Zynex, Inc., please click your way over to the company’s website at: www.ZynexMed.com
Zix, the leader in email encryption services, announced the release of a new and improved version of ZixPort®, a secure Web portal. This upgraded version includes message recall and two-factor authorization, providing increased control and flexibility of encrypted email messages to compliance and security officers.
ZixPort is a delivery method that enables bidirectional email encryption for recipients who do not have ZixCorp® Email Encryption Services. ZixPort is available to any recipient with an Internet browser, and can be easily accessed on mobile devices as well. The message recall feature gives compliance, security officers, and administrators the ability to remove messages from ZixPort if an email is sent to the wrong recipient or the wrong file is mistakenly attached.
The second new feature in this release of ZixPort is two-factor authentication in a streamlined, user-friendly process that is perfectly suited for financial institutions and government organizations that require additional security without inconveniencing recipients. This new authentication method will be the third authentication method offered with ZixPort, along with integration with customer’s existing Single Sing-on technology and solutions from third-party two-factor authentication providers.
“ZixCorp has set the bar in industry-leading email encryption services. We are constantly investing in our products to ensure that we exceed customer demands, as well as meet our commitment to deliver innovative, easy-to-use secure email,” said Rick Spurr, ZixCorp’s Chairman and Chief Executive Officer. “ZixPort is an essential delivery method in our portfolio of services, and the new features of ZixPort enhance control and flexibility for our customers and continue to extend our lead in the market.”
The new message recall feature is scheduled to be rolled out in June 2012. Two-factor authentication is expected to be commercially available in August 2012. For additional information, please visit ZixCorp’s booth – no. 85 – at the Gartner Security & Risk Management Summit on June 11 – 14, 2012, or contact 866-257-4949.
For more information, please visit www.zixcorp.com
Today's Top 3
The QualityStocks Public Company Sponsor News